Free Guide: Everything You Need to Know About KRAS G12C Testing in NSCLC

Activating mutations in KRAS are one of the most prevalent oncogenic drivers in non-small cell lung cancer (NSCLC) and mutant KRAS remains a challenging to target. Learn how next-generation sequencing can simultaneously analyze relevant biomarkers and co-mutations essential to understanding the genomic landscape of mutant KRAS.

Please fill out the form below to download our guide with information about methods for identifying mutations in KRAS.

  • - Select -
  • Canada
  • United States
Are you interested in receiving a quote or demo about the Oncomine NGS Assays or the Genexus NGS System for KRAS biomarker testing in clinical research?

I agree for the Thermo Fisher Scientific group (thermofisher.com/legalentities) to contact me by e-mail and telephone to inform me of events, products, services and promotions offered in connection with the brands Thermo Scientific™ Applied Biosystems™, Invitrogen™, GibcoTM, Ion Torrent™, Unity Lab Services™, Fisher Scientific™

I can withdraw my consent and unsubscribe at any time by emailing reply@thermofisher.com